P563 Stopping anti-TNFα monotherapy in Crohn's disease patients in deep remission and favourable disease characteristics is associated with a high rate of relapse

Abstract Background Stopping anti-TNFα therapy in IBD patients may positively impact safety, cost and psychologic burden of disease management. Deep remission and absence of bad prognostic factors have been suggested by previous studies as potential predictors and provisions of successful therapy wi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2018-01, Vol.12 (supplement_1), p.S391-S391
Main Authors: Soufleris, K, Kafalis, N, Fasoulas, K, Lazaraki, G, Pilpilidis, I, Tzilves, D, Giouleme, O
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Stopping anti-TNFα therapy in IBD patients may positively impact safety, cost and psychologic burden of disease management. Deep remission and absence of bad prognostic factors have been suggested by previous studies as potential predictors and provisions of successful therapy withdrawal. The aim of the study was to evaluate the outcome of stopping anti TNFa monotherapy in Crohn's disease patients with characteristics proposed to favour therapy de-escalation or interruption. Methods Patients with Crohn's disease in remission who stopped anti-TNFα monotherapy were followed for relapse. The study only included patients in deep biologic (CRP
ISSN:1873-9946
1876-4479
DOI:10.1093/ecco-jcc/jjx180.690